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The efforts toward individualized medicine have constantly increased in an attempt
to improve treatment options. These efforts have led to the development of small
molecules which target specific molecular pathways involved in cancer progression.
We have reviewed preclinical studies of sunitinib that incorporate sex as a covariate to
explore possible sex-based differences in pharmacokinetics and drug–drug interactions
(DDI) to attempt a relationship with published clinical outputs. We observed that
covariate sex is lacking in most clinical outcome reports and suggest a series of
ethic-based proposals to improve research activities and identify relevant different sex
outcomes. We propose a deeper integration of preclinical, clinical, and translational
research addressing statistical and clinical significance jointly; to embed specific sex-
divergent endpoints to evaluate possible gender differences objectively during all stages
of research; to pay greater attention to sex-divergent outcomes in polypharmacy
scenarios, DDI and bioequivalence studies; the clear reporting of preclinical and clinical
findings regarding sex-divergent outcomes; as well as to encourage the active role of
scientists and the pharmaceutical industry to foster a new scientific culture through
their research programs, practice, and participation in editorial boards and Institutional
Ethics Review Boards (IRBs) and Research Ethics Committees (RECs). We establish the
IRB/REC as the centerpiece for the implementation of these proposals. We suggest the
expansion of its competence to follow up clinical trials to ensure that sex differences are
addressed and recognized; to engage in data monitoring committees to improve clinical
research cooperation and ethically address those potential clinical outcome differences
between male and female patients to analyze their social and clinical implications in
research and healthcare policies.
Keywords: sunitinib, sex-divergent pharmacokinetics, clinical outcomes, covariate sex, research ethics, IRB,
ELSI
Abbreviations: AD, adaptive design; DDI, drug–drug interaction; DMC, data monitoring committees; GIST, gastrointestinal
stromal tumor; IRB, Institutional Review Board; mRCC, metastatic renal cell carcinoma; RCC, renal cell carcinoma; REC,
Research Ethics Committee; TDM, therapeutic drug monitoring; TK, tyrosine kinase.
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INTRODUCTION
The research drive toward personalized medicine has grown
exponentially during the last years in an attempt to improve
therapeutic outcomes putting the patient at the center of the
healthcare system. The shift toward precision medicine has
deeply focused on diagnosis and treatment, particularly in the
oncology field (Prasad et al., 2016). The development of small
molecules to inhibit specific molecular pathways in oncology led
to pioneer approval in 2001 of imatinib, a signal transduction
inhibitor targeting TK cKIT, PDGFα/β, and Bcr-Abl receptors for
the treatment of GIST (Dagher et al., 2002). Following imatinib,
a series of other TK inhibitors were introduced and approved
providing new therapeutic options for a variety of cancers (Wu
et al., 2016). Simultaneously, further personalized strategies for
patient treatment combining TDM and dose individualization
were being developed (de Wit et al., 2015; Stinchcombe, 2017).
The emphases on personalized treatment to improve
individual therapeutic outcomes has encouraged the
identification of clinical outcomes differences between male
and female patients (Figure 1). Based on a deeper understanding
of their nature, sex differences have been grouped in four types
(Becker et al., 2017): (1) qualitative sex differences where male
and female sexes show different behavior; (2) quantitative sex
differences when there is greater response in one of the sexes; (3)
convergent sex differences in which both sexes display the same
behavior but the pathways that mediate it are different, and lastly
(4) population sex differences where the presence of a specific
behavior differs in proportion between males and females. The
need to provide a deeper understanding and relevance of these
differences has moved regulatory and scientific agencies to
issued recommendations encouraging the study of their impact
on therapeutic outcomes (Bren, 2005). Although the overall
implementation has been scarce (Fisher and Ronald, 2010) for
different practical reasons (Bolon, 2010; Fisher and Ronald,
2010; Cahill, 2014), there have been various reports addressing
FIGURE 1 | Number of publications in PubMed dealing with sex-divergent
and personalized medicine. The searching terms were “personalized
medicine” and [“sex-differences” OR “sex-divergent” OR “sex-dependent”] for
sex-differences.
potential sex-based differences in drug efficacy and toxicity, at
least from a descriptive point of view (Ostrom et al., 2014; Sun
et al., 2015). In a large review of clinical studies, differences in
efficacy were reported in 1 out of 68 drugs for 36 indications
(Gartlehner et al., 2010). However, the authors remarked that
“most available evidence was compromised by methodological
limitations” precluding any deep inquiry about the impact of sex
differences on efficacy and toxicity. Further cumulative evidence
has matured in various fields (Klein et al., 2015) including
neurosciences (Cahill, 2006, 2017), neurodegenerative diseases
(Bove and Chitnis, 2013; Canevelli et al., 2017), medication
use and treatment adherence (Chen et al., 2014; Manteuffel
et al., 2014), incidence of DDI (Bowlin et al., 2013) as well as
clinical and preclinical research (Franconi and Campesi, 2014a,b;
Mazure, 2016; Segarra et al., 2016). This evidence has pushed
forward more clearly the need to address potential sex-based
differential clinical effects on male and female patients with the
inclusion of covariate sex in the outcome analysis for the benefit
of patients (Segarra et al., 2016; Cahill, 2017).
Tyrosine Kinase Inhibitor Sunitinib
Tyrosine kinase receptors are a subset of protein kinases involved
in numerous cellular processes (Roskoski, 2015). Because of
their extent and large cell functionality and involvement in
pathogenesis and disease progression pathways, intensive efforts
to identify and validate therapeutic targets have taken place,
leading to the subsequent development of molecules targeting
specific TK receptors (Chow and Eckhardt, 2007; Goueli, 2017)
which have delivered significant improved clinical outcomes (Wu
et al., 2015, 2016).
Sunitinib is a small molecule, able to inhibit a multiplicity
of TK receptors including the platelet-derived growth factors
PDGFRα/β, the colony stimulating factor type I (CSF-1R), the
vascular endothelium growth factor (VEGFR), the stem cell
factor c-KIT, and the fetal liver TK receptor 3 (FLT3) amongst
others (Faivre et al., 2006; Papaetis and Syrigos, 2009). Owing
to this ability to inhibit diverse multiple TK receptors, sunitinib
has shown capacity to arrest angiogenesis, metastasis and tumor
progression (van Erp et al., 2009). These features have led to its
therapeutic application in RCC (Motzer et al., 2016), metastatic
RCC (Schmid and Gore, 2016) including brain metastasis
(Lombardi et al., 2014), GIST resistant to imatinib, metastatic
GIST (Khosravan et al., 2016), and pancreatic neuroendocrine
tumors (Blumenthal et al., 2012; Capozzi et al., 2016).
We have carried out the analysis of the translational impact
of covariate sex on an anticancer drug such as sunitinib and
compiled various ethic proposals to better address the impact
of sex on clinical outcomes and trigger scientific discussion to
improve the design of future research.
TRANSLATIONAL APPROACH OF
COVARIATE SEX ON SUNITINIB
The translational relevance and clinical interest of covariate sex
applied to sunitinib treatment has been assessed at different
levels: (1) the possible sex-divergent pharmacokinetics of
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sunitinib and (2) the differential effect of DDI on male and female
sexes.
Covariate Sex Effect on
Pharmacokinetics
The effect of sex differences on the pharmacokinetics and
tissue distribution of TK inhibitor sunitinib was evaluated in a
preclinical mouse model (Lau et al., 2015; Liew et al., 2017). In
both studies, statistically significant differences between sunitinib
exposure in male and female mice were found in plasma, liver,
brain, and kidney tissue. This finding may have significant clinical
relevance owing the therapeutic use of sunitinib against brain
tumors, RCC, and metastatic RCC, two target tissues (brain and
kidneys) that showed marked differences between sexes: female
mice show higher sunitinib penetration and exposure in brain
tissue versus male mice while male mice have greater sunitinib
penetration in kidneys versus female mice (Table 1).
An exploratory attempt to correlate these findings with clinical
outcomes in male and female patients was previously done,
although it was limited to individual cases and case series reports
of patients treated with sunitinib (Segarra et al., 2016). The
individual cases seemed to suggest that female patients achieved
better response to brain tumor than male patients which was
concordant with literature observations showing better outcomes
and lower incidence of brain tumor in female patients (Sun et al.,
2015). In addition, apparent better RCC therapeutic outcomes
were observed in male patients (Houk et al., 2009; Bamias et al.,
2013). An additional observation was the higher incidence of
adverse effects, including various fatal liver failure cases in female
patients (van der Veldt et al., 2008; Akaza et al., 2015; Narjoz et al.,
2015).
Last, sex-divergent differences in clearance and volume of
distribution parameters between male and female patients have
been shown (Khosravan et al., 2016) which suggests clinical
translatability from preclinical studies. The pharmacokinetic
differences between male and female sexes may be responsible
for the large variability and lack of efficacy encountered in
some clinical trials which led to the change or discontinuation
of treatment (Lankheet et al., 2014b; Akaza et al., 2015; Gore
et al., 2015; Barrios et al., 2016; Domagała-Haduch et al., 2016)
likely due to poor dosing adjustment since plasma concentration
alone may not ensure precise dose adjustment (Houk et al.,
2010; Lankheet et al., 2014b) as seen in most TK inhibitors
(de Wit et al., 2015; Kotecki and Penel, 2016). This is especially
relevant if sex differences lead to tissue exposure differences as
observed in the preclinical studies, are not taken into account.
The translatability interpretation of the preclinical data shows
higher sunitinib plasma exposure and uptake in brain in female
mice and higher sunitinib penetration in kidney tissue in male
mice which may anticipate the clinical differences observed in
patients (Segarra et al., 2016).
Effect on DDI Outcomes
The covariate sex may also have a significant impact on
DDI outcomes given the fact of cancer patient polymedication
(Leblanc et al., 2015) including those undergoing sunitinib
treatment (Bilbao-Meseguer et al., 2015). Sex-based DDI
outcome differences were observed upon coadministration of
sunitinib with selected NSAIDs, used to reduce cancer pain or
side effects related to the treatment (Ripamonti et al., 2014;
Hammer et al., 2016; Mercadante and Portenoy, 2016). In
preclinical studies, dramatic sunitinib plasma and tissue exposure
effects were observed after coadministration with ibuprofen (Lau
et al., 2015), paracetamol (Liew et al., 2017) or diclofenac (Chew
et al., 2017). These effects included changes of sunitinib plasma
exposure and most importantly, changes in brain, liver, and
kidney sunitinib penetration that were different in male and
female mice showing sex-different plasma-tissue DDI outcomes
(Table 1): diclofenac and paracetamol decreased plasma exposure
in male mice which compares with a general reduction of
sunitinib exposure in tissues of interest. However, female mice
did not show any DDI effect in plasma and sunitinib exposure
remained unchanged eventhough large effects did take place in
tissues. Last, ibuprofen showed the opposite behavior: no effect
was observed in sunitinib plasma exposure in male mice while
significant changes took place in tissues. Similarly, after multiple
dose administration to mice (Tan et al., 2016), sex-divergent
concentration changes were also observed in plasma and tissues,
although statistical significance was attained only upon sunitinib
coadministration with paracetamol or ibuprofen (Table 2).
Likewise, clinical observations identified numerous DDI
with sunitinib (Bilbao-Meseguer et al., 2015), including DDI
TABLE 1 | Effect of DDI on plasma and tissue AUC0→∞ (versus control groups) after a single dose (60 mg/kg) administration of sunitinib orally.
GROUP PLASMA LIVER KIDNEY BRAIN
Male Female Male Female Male Female Male Female
Control ICR >+++ >+++ >+++ >+++
Diclofenac1 ↓∗∗∗ ↔ ↓∗∗∗ ↑∗∗∗ ↓∗∗∗ ↑∗∗∗ ↓∗∗∗ ↓∗∗∗
Paracetamol2 ↓∗ ↔ ↓∗∗∗ ↓∗∗∗ ↓∗∗∗ ↓∗∗∗ ↓∗∗∗ ↓∗∗∗
Control Balb/c >+ >+++ >+++ >+++
Ibuprofen3 ↔ ↓∗∗ ↑∗∗∗ ↓∗∗∗ ↑∗∗∗ ↓∗∗∗ ↑∗∗∗ ↓∗∗∗
+Significant differences between genders in the control groups: +p < 0.05, +++p < 0.001. ∗Significant differences with the respective control group: ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001. 1Adapted from Chew et al. (2017). 2Adapted from Liew et al. (2017). 3Adapted from Lau et al. (2015). DDI studies with diclofenac and
paracetamol were carried out in ICR mice and the DDI study with ibuprofen in Balb/c mice. Control ICR and Balb/c are also included showing whether male or female
mice attained greater AUC0→∞.
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TABLE 2 | Trend effect of DDI on plasma and tissue concentrations (versus control groups) after multiple dose administration of sunitinib orally in ICR mice.
GROUP PLASMA LIVER KIDNEY BRAIN
Male Female Male Female Male Female Male Female
Control ICR > > > >
Diclofenac ↓ ↓ ↓ ↔ ↓ ↓ ↑ ↓
Paracetamol ↓ ↑ ↑∗ ↓ ↑∗ ↓ ↑ ↓
Ibuprofen ↑ ↓∗ ↑∗∗ ↓ ↑ ↓ ↑ ↓∗∗∗
Mefenamic Acid ↑ ↓ ↑ ↑ ↓ ↓ ↔ ↓
∗Significant differences with the respective control group: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Adapted from Tan et al. (2016).
which showed differential effects on male and female patients
(Bowlin et al., 2013): female patients showed significantly higher
frequency of DDI causing increased toxicity related to the target
enzyme. This higher rate of DDI was observed also with other TK
receptor inhibitors, imatinib, and erlotinib (Bowlin et al., 2013),
making necessary to evaluate appropriately the selection of pain
management drugs in cancer patients.
Translatability in Therapeutic Drug
Monitoring
There is an often forgotten translatability issue: TDM. Usually,
TDM protocols are developed during the clinical stage and
focused on a surrogate parameter (marker) that indicates
treatment efficacy or toxicity. Generally, these surrogate
parameters are either drug or biomarker concentrations in a
measurable matrix (e.g., plasma, blood or urine) or genotyping
able to relate to efficacy or toxicity (Eliasson et al., 2013).
The relevance of addressing sex as a covariate strikes hard
at the current pharmacotherapy practice and management
of TK inhibitors (Lankheet et al., 2014a,b) owing to the
polypharmacy scenario of cancer patients (Leblanc et al.,
2015): several preclinical DDI studies of sunitinib with selected
NSAIDs, have shown that the DDI effects on plasma and
tissue were different in male and female mice. Particularly
relevant for TDM were the observations that paracetamol and
diclofenac caused a reduction of sunitinib plasma exposure
in male mice but not in female mice. However, ibuprofen
reduced sunitinib exposure in female mice. In all cases, the
reduction of sunitinib plasma exposure was accompanied with
a subsequent reduction in tissue penetration (Table 1). Thus,
plasma concentration based TDM would probably detect a DDI
with paracetamol or diclofenac in a male patient and a possible
DDI with ibuprofen in a female patient. Then, subsequent
dosage adjustment may be carried out. However, it is likely that
the DDI would remain undetected in female patients taking
paracetamol or diclofenac and in male patients taking ibuprofen.
In this case, their coadministration would mask changes in
brain, liver or kidney sunitinib penetration and exposure as
these do not correlate with the events occurring in plasma
(Table 1). Thus, if monitored parameters remain unchanged in
plasma (e.g., plasma concentrations), or cannot be measured
in tissues, then, understanding male-female DDI differential
effects becomes essential to carry out TDM successfully (Gao
et al., 2012; Takasaki et al., 2017). Else, there exists a risk to
diminish treatment efficacy or even to treatment failure (e.g., in
brain tumor and RCC female patients with concomitant use
of paracetamol) or to increase toxicity due to higher liver
sunitinib exposure upon coadministration with diclofenac or
paracetamol in female patients or with ibuprofen in male
patients.
Furthermore, the routine introduction of biomarkers in TDM
is an intense research area (Eliasson et al., 2013). This would
ensure that TDM captures possible sex-divergent expression of
sunitinib clinical outcomes to evaluate the response, the efficacy
and the toxicity in male or female patients (Planchard et al., 2009;
Wendler and Wehling, 2010; Moon et al., 2013). This ability
to integrate covariate sex effects in preclinical data with clinical
development outputs may anticipate the goodness, suitability
and reliability of sunitinib TDM protocols to anticipate and
detect differential outcomes between male and female patients
(Franconi and Campesi, 2014a,b).
ROLE OF SEX IN FUTURE DRUG
DEVELOPMENT CLINICAL RESEARCH
The analysis of sunitinib therapeutic outputs in male and female
patients, although limited, allows the identification of various
domains which are relevant to sex-based clinical research: the
introduction of sex as a covariate in the analysis, the integrative
translational research approach, the effects on pharmacotherapy
management and patient involvement amongst other domains.
All these efforts would lead to greater health equity between male
and female patients (Chapman, 2010).
Contextualizing Covariate Sex
The specific clinical importance of sex differences has increased
scientific awareness to study them in a systematic manner,
particularly in clinical research (Mazure and Jones, 2015).
However, as it has been reported recently, their impact on
pharmacokinetics and therapeutics has been considered of
relatively low importance and in general, male sex has been
used as a proxy for female sex (Brooks and Clayton, 2017;
Cahill and Hall, 2017). This approach has generated a vacuum
of high quality evidence that would have allowed a univocal
understanding of the potential influence of sex differences on
the pathogenesis, disease progression and in the last analysis,
the therapeutic outcomes (Picillo et al., 2017). The quest for
precision and personalized medicine has been “deeply harmful,
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in particular to the health of women” (Cahill, 2017) as this
information is lacking for developing adequate therapeutic
protocols. This possible scenario may be observed with the
clinical use of sunitinib to treat brain tumors, RCC and mRCC
as well as with the incidence of adverse effects. The reports
of the main sunitinib clinical trials differentiate between male
and female patients in the demographic data section but fail to
report the efficacy and toxicity outcomes differentiating between
male and female patients (Segarra et al., 2016). This lack of
knowledge may create a gap that could lead, for example, to
the coadministration of a less suitable pain management drug
(e.g., paracetamol) to a brain tumor female patient. In turn, this
may lead to diminish the drug efficacy, more over without TDM
revealing any change of the plasma concentration of sunitinib,
and thus possibly remaining undetected.
Higher quality evidence addressing possible sex differences
impact on therapeutics is lacking. This makes difficult to identify
the best and more appropriate pharmacotherapy approaches.
However, new opportunities to bridge the gap between male and
female patients are emerging upon the paradigm shift taking
place in the drug discovery and development process. In fact,
some of the differences between sexes were found the hard way,
that is to say, once the drug is available to a large public and
clinical response differences begin to surface (Cahill and Hall,
2017). Thus, the current shift from a linear drug development
process or “bench to bedside,” where molecules overcome specific
cut-off values to progress to the next stage in a funnel-like
competition, toward a translational model (“bedside to bench”) is
allowing the identification of patient oriented selection strategies
(Chorghade et al., 2017). Thus the “bedside to bench” approach
versus the “bench to bedside” traditional approach takes advantage
of the large number of patients which have already used the drug
to identify new therapeutic indications or at risk populations.
These findings are followed by sets of preclinical and paraclinical
studies which incorporate the novel features identified in the
clinical trials and safety studies that brought forward the potential
new indication (Lieu et al., 2013). This approach may identify
differences in clinical outcomes between male-female patients
to conduct treatment adjustment based on each patient sex and
enhance further patient oriented research (Fisher and Ronald,
2010).
Translational Preclinical Research
The life cycle of a drug molecule described above is no
longer linear with the pharmaceutical companies increasingly
looking for additional therapeutic applications of their marketed
products, expanding their therapeutic potential as well as
maximizing their financial and scientific investments (Fisher and
Ronald, 2010). Cancer therapeutics has successfully benefit from
this “bedside-to-bench-and-back-to-bedside” approach. Several
marketed molecules targeting drivers of oncogenic processes
have increased their target repertoire adding other cancer types
or specific patient populations that could benefit from them
(Lieu et al., 2013): succinct empirical observations gathered from
everyday clinical practice were revisited in preclinical models to
identify and understand their underlying mechanisms. Tyrosine
kinase inhibitor sunitinib illustrates well how preclinical studies
carried out post-marketing offered improved treatments (Carlisle
et al., 2016).
Various aspects are needed to ensure validity of this
translational approach to identify sex-based differences. At
cellular level, the sex origin of the cell lines affects the
pharmacological outcome (Nunes et al., 2014) owing to different
internal cellular mechanisms (Sun et al., 2015) or different
expression levels of targeted receptors, conditioned by the male-
female genetic makeup of the cell (Hägerstrand et al., 2006).
Cellular sex-based differences have a clear and decisive effect
on the possible sex-divergent pharmacokinetics of sunitinib:
First, intracellular drug metabolizing enzymes are involved
in the biotransformation (Sakuma et al., 2009; Waxman
and Holloway, 2009) and generation of active metabolites
(e.g., sunitinib’s demethyl metabolite). Second, sex-divergent
membrane transporters amount and localization (Cui et al.,
2009; Hou et al., 2014; Joseph et al., 2015) may restrict tissue
penetration and active excretion processes differently (Bebawy
and Chetty, 2009; Franconi and Campesi, 2014b; Mazure, 2016).
Furthermore, the study of the effects in both sexes should
include studies evaluating the whole lifespan in preclinical animal
models, to study the impact of sex hormones at different ages, as
they have been linked to clinical outcome differences in humans
(Gur and Gur, 2016).
Eventhough sex differences between male and female subjects
are rooted at the cellular level (e.g., chromosomal determination),
they affect the therapeutic response of the subject (Marazziti
et al., 2013; Naidoo et al., 2014; Sun et al., 2015). These divergent
outcomes demand specific in vitro and in vivo study designs
able to assess the impact of each singular difference upon
which particular emphasis is required for P450 enzymes and
membrane transporters (Cummins et al., 2002). Therefore, to
fully identify the impact of sex on therapeutics seems necessary
to develop post-marketing preclinical studies with a clinical
outlook taking into account diverse clinical scenarios (Chorghade
et al., 2017). Amongst these scenarios, it is crucial to include
polypharmacy situations to anticipate adverse events due to
the coadministration of various drugs (Zhang et al., 2011).
Because female patients are more susceptible to medication use
(Bowlin et al., 2013), the analysis of potential DDI in animal
models may provide valuable information about the impact and
translatability on the efficacy and toxicity to optimize therapy in
female patients (Kotecki and Penel, 2016; Peck, 2016) or even to
infer novel therapeutic approaches (Lim et al., 2010; Chew et al.,
2012; Tan et al., 2013, 2016). In addition, these studies should
complement other preclinical studies and support the efforts
to identify sex-divergent outcomes (e.g., pharmacokinetics and
tissue distribution) and translate the findings to clinically viable
options with a better understanding of disease progression, lower
attrition rate and improved predictability from basic research
(Maienschein et al., 2008).
The Meaning of Sex as a Covariate
The significance of the covariate sex in crucial to identify possible
differences. Women have gradually increased participation in
clinical trials (Pinnow et al., 2009) and their participation remains
essential to assess whether sex-based differential outcomes
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exist. If differences do not exist, either population (male or
female patients) would provide reliable results regarding the
performance of the drug. But this premise cannot be assumed
lightly and it needs to be proven in clinical trials that include
male and female patients, taking into account the higher risks that
female patients may endure (e.g., risk of unknown teratogenic
effects).
The evaluation of sex-divergent therapeutic outcomes requires
an interpretation beyond the dichotomous cut-off probability
p-value, e.g., p < 0.05 (Wasserstein and Lazar, 2016). Otherwise,
a mismatch may develop between the objective endpoints (the
effect of sex on the specific measurable clinical outcome)
and the statistical criteria limited by the sample size and
measurement precision used to calculate the p-value (van
Rijn et al., 2017). To overcome this risk, it is crucial to
report the p-value of the results always, regardless whether
it is higher, lower or equal to 0.05: this reflects the degree
of influence of the covariate on the feature which is being
evaluated (Kyriacou, 2016). Furthermore, first, it allows an
evidence-based approach to address the impact of sex differences
on therapeutic outcomes of male versus female patients and,
second a holistic approach with a continuum scope linking
clinical practice and patient behavior. This approach may
ensure whether a non-significant or a significant p-value (based
on a pre-established p-value) is clinically relevant. Factors
such as higher medication use including non-prescribed and
self-medication, comorbidities and age differences in female
patient population (Bren, 2005; Regitz-Zagrosek, 2014) are
aspects that may influence the pharmacotherapy outcome and
make covariate sex clinically significant. Other aspects related
to patient behavior such as lesser access to healthcare and lack
of adherence in female patients (Chen et al., 2014; Franconi
and Campesi, 2014b; Manteuffel et al., 2014) may also lead
to unexpected differential outcomes between male and female
patients.
The first steps toward precision medicine appeal to the
principal investigators (PI), scientists and study coordinators for
implementation of sex-differentiated data analysis in the results
section of the study report, regardless of the p-value achieved.
This action seems essential to evaluate the impact of covariate sex
on therapeutics, to assess whether these differences exist and how
deeply they modulate clinical outcomes. Establishing this link
between the p-value and its clinical significance (e.g., differences
observed in clinical practice, in patient care and behavior) can
indicate whether differential pharmacotherapy approaches in
male and female patients are needed. If sex difference impact
is inferred, then therapeutics may be adjusted and precision
medicine realized (de Wit et al., 2015).
We would greatly encourage researchers and authors to
implement sex-differentiated reporting of efficacy, toxicity and
endpoint attainment, as well as editors to require this analysis
in their scientific publications (Blaustein, 2012; Prager, 2017;
Rippon et al., 2017). Furthermore, comparison of results between
sexes in upcoming studies, including bioequivalence studies,
adaptive clinical trial designs (Lieu et al., 2013), as well as
revision of previously published studies (especially large clinical
trials), would provide greater degree of inference and would yield
greater patient benefit. In addition, these actions would provide
better elements to the IRB and REC to evaluate future research
proposals more efficiently (Harman et al., 2015).
ROLE OF THE INSTITUTIONAL REVIEW
BOARD
The IRB and/or the REC are the check point to ensure the clinical
research proposal is sound and carried out ethically. This mission
requires from the reviewing process to assess whether the goals
and objectives of the proposal are rigorous, the pursued outcomes
present a logical clinical expectation and are methodologically
achievable (MacKay, 2001). This assessment ensures the main
aim of the IRB/REC to protect the participant subjects, the
institution conducting the research (Guillemin et al., 2012)
and warrants avoiding unnecessary patient burden (Carlisle
et al., 2016). Obviously this review process relies on accurate,
significant, and relevant information; the independence (absence
of conflict of interests) and the integrity of its members (Harman
et al., 2015; Macpherson et al., 2017) to develop a constructive
decision within a reasonable uncertainty limits (Kimmelman,
2012) which leads to subject selection and the initiation of the
clinical trial (Chalmers et al., 2013; Kimmelman and London,
2015).
Embed Covariate Sex in the Review
Process
As drug developers expand the clinical use of their marketed
drugs based on the observations from large clinical trials, the best
way to ensure the analysis of the effect of sex upon an exploratory
clinical outcome is requiring its inclusion in the study protocol. In
this “bedside-to-bench-and-back-to-bedside” approach, the study
proposals need to be sufficiently justified and supported with
published preclinical information to demonstrate the rationale
for the new clinical study/trial application. The IRB should
request a preliminary assessment of sex-divergent outcomes
based on the observations that lead to the new study application.
In addition all clinically relevant evidence (“bedside”) of prior
clinical trials submitted to the IRB/REC may include a posterior
evaluation of possible sex-divergent outcomes and address how
the endpoints may assess the difference between male and female
patients. The supporting preclinical (“bench”) data should include
details about the sex of the cells and animals used and an analysis
of sex as a covariate in cell-based assays (e.g., potency, selectivity,
eﬄux and uptake processes, etc.) as well as animal studies (e.g.,
pharmacokinetic, toxicology and efficacy studies) carried out to
anticipate its relevance in therapeutics (Mazure, 2016; Prager,
2017). Similarly, when a traditional “bench-to-bedside” approach
is pursued, the IRB/REC may ensure the analysis of sex effects is
evaluated along each preclinical stage without assuming a specific
outcome as it has been shown that it may modify the research
procedures (Maienschein et al., 2008).
The compilation of this information would allow the IRB/REC
to reach a decision regarding the research proposal taking into
account whether possible differences between male and female
patients are addressed properly with a minimal risk of patient
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burden (Carlisle et al., 2016). Furthermore, the IRB should
push to ensure that upcoming clinical trials are “designed with
stratified randomization by sex” (Prager, 2017). This design may
guaranty that the sex-divergent therapeutic outcomes are found
or rejected based on clinical significance (Fisher and Ronald,
2010). In this context, we would encourage Regulatory Agencies
and the pharmaceutical industry to incorporate this approach to
bioequivalence studies, and include sufficient number of male
and female subjects to ensure that possible sex differences are
detected.
Expanding the Role and Responsibility of
the IRB/REC and the Pharmaceutical
Industry
The IRB/REC can contribute largely to identify sex-different
clinical outcomes not only with the revision and approval of
the study protocol but also following up the development of the
clinical trial. This would require expanding its competency and
to interact with the research team or pharmaceutical company
sponsoring the study on a pre-agreed schedule. This operating
procedure would empower the IRB/REC to pursue a variety of
actions regarding the inclusion of the assessment of covariate sex:
• First, it would ensure that the clinical trial is not stopped
upon achieving a specific endpoint without sufficient
clinical significance and clarity to assess the outcomes
between sexes, especially when a novel indication is pursued
(Henderson et al., 2015). The IRB may require scientists to
evaluate and report back on a regular basis to ensure the
accomplishment of the outcomes (Coleman and Bouësseau,
2008).
• Second, the IRB should push for the full publication
of the aggregate results as well as categorized by sex
when the sponsoring entity issues the final report. In
fact, transparency of the results reports is a worthwhile
target to pursue: appropriate reporting of data fosters
knowledge dissemination and therefore, promotes
beneficial information and prevents harmful research, or
at least avoids using resources unnecessary. In this sense, it
may be useful for researchers to have some kind of reporting
guidelines to add to the submission of the research proposal
at the review process (Nicholls et al., 2016).
• Third, the IRB, jointly with the leading scientists of the
study, may foster the implementation of AD clinical trials
to better determine possible endpoint differences between
male and female subjects or patients (Coffey et al., 2012;
Chow, 2014). Similarly, the AD clinical trials may improve
the suitability of exploratory biomarkers for each sex
category (Antoniou et al., 2016).
• Last, the IRB may engage and participate in the DMC,
even when the scope of the DMC involves several clinical
research centers disseminated in different countries. Their
participation may be widened rather than limited to overall
management and coordination tasks. It may assure that
no information which could affect the informed consent
(e.g., possible sex-divergent adverse events) is withheld,
new information is provided to the scientists conducting
the clinical trial as well as the integrity of the study is
preserved (Chalmers et al., 2013).
The contribution of the IRBs and RECs to assess sex
differences goes beyond the review process task given the nature
of the findings. Their assessment “matters scientifically, it matters
ethically and it matters socially” (Maienschein et al., 2008)
as it aims to improve population health and guaranty health
equality taking into account the individual (male or female)
characteristics (Chapman, 2010). Although this expanding role
is necessary, a review of the means available for each IRB and
REC to pursue it is needed: IRBs and RECs may be ill-equipped
regarding resources available, training and formation of their
members, including scientific training to fully understand the
research proposals (Coleman and Bouësseau, 2008; Guillemin
et al., 2012). Thus, inclusion and empowering competent and
knowledgeable external members in the research and practice
deliberative process may help, at least initially, solving the lack
of resources for an expanding role of the IRBs and RECs (Bennet
and Chapman, 2010).
CONCLUDING REMARKS
The translational perspective of covariate sex integrating
preclinical and clinical evidence of TK sunitinib suggests
the importance of addressing systematically sex-divergent
therapeutic outcomes. This information should be available to
foster and enhance future clinical research as well as to improve
current treatment options. The IRBs and RECs, together with the
pharmaceutical industry and other research sponsors play a key
role to ensure that possible differences between male and female
patients are identified, taken into account and an assessment of
their clinical relevance performed. Empowering and expanding
the role of IRB and REC to pursue this analysis may result in
valuable inputs and improve future clinical trials outputs.
Overall, although we have focused our evidence in a specific
drug used in oncology, these proposals and views may be
incorporated in other therapeutic areas. Furthermore, their
review could serve to echo and foster scientific discussion at
the technical and ethical level to emphasize the importance
of developing studies addressing sex differences that would
render the possibility to personalize treatments and benefit
patients.
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